Pairing Cancer Biomarkers to Biomedicine

EBioMedicine. 2017 Nov:25:1-2. doi: 10.1016/j.ebiom.2017.10.025. Epub 2017 Oct 27.

Authors

Seung Ho Shin¹, Zigang Dong²

Affiliations

¹ The Hormel Institute, University of Minnesota, Austin, MN 55912, United States.
² The Hormel Institute, University of Minnesota, Austin, MN 55912, United States. Electronic address: zgdong@hi.umn.edu.

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Biomarkers, Tumor* / genetics
Biomarkers, Tumor* / metabolism
Colonic Neoplasms / drug therapy
Colonic Neoplasms / metabolism
Humans
Molecular Targeted Therapy / methods*
Nivolumab
Precision Medicine / methods*
Treatment Outcome
beta Catenin / antagonists & inhibitors*
beta Catenin / metabolism

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Biomarkers, Tumor
CTNNB1 protein, human
beta Catenin
Nivolumab
pembrolizumab